The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer
Open accessAbstract
Pancreatic cancer is a deadly disease that is usually diagnosed in the advanced stages when few effective therapies are available. Given the aggressive clinical course of this disease and lack of good treatment options, the development of new therapeutic agents for the treatment of pancreatic cancer is of the upmost importance. Several pathways that have shown to contribute to pancreatic cancer progression are negatively regulated by the tumor suppressor protein phosphatase 2A (PP2A). Here, the endogenous inhibitors of PP2A, SET (also known as I2PP2A) and cancerous inhibitor of PP2A (CIP2A), were shown to be overexpressed in human pancreatic cancer, contributing to decreased PP2A activity and overexpression and stabilization of the oncoprotein c-Myc, a key PP2A target. Knockdown of SET or CIP2A increases PP2A activity, increases c-Myc degradation, and decreases the tumorigenic potential of pancreatic cancer cell lines both in vitro and in vivo. Moreover, treatment with a novel SET inhibitor, OP449, pharmacologically recapitulates the phenotypes and significantly reduces proliferation and tumorigenic potential of several pancreatic cancer cell lines, with an accompanying attenuation of cell growth and survival signaling. Furthermore, primary cells from patients with pancreatic cancer were sensitive to OP449 treatment, indicating that PP2A-regulated pathways are highly relevant to this deadly disease. Implications: The PP2A inhibitors SET and CIP2A are overexpressed in human pancreatic cancer and are important for pancreatic cancer cell growth and transformation; thus, antagonizing SET and/or CIP2A may be an innovative approach for the treatment of human pancreatic cancer. Mol Cancer Res; 12(6); 924–39. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This is a very important finding because the therapeutic effects of inhibition of CIP2A protein expression have been validated by numerous studies [6 -8,10 -12,21].”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stabilityPreprint
Sears, R. C., Nuckolls, F., Haura, E. B., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,411
Self-citationYeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
Self-citationCIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Self-citationRegulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation
Chen, J., Martin, B. L., & Brautigan, D. L. (1992) · Science · doi:10.1126/science.1325671 · Cited by 601
Fan, Z., Beresford, P. J., Oh, D. Y., Zhang, D., & Lieberman, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00150-8 · Cited by 541
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Cited by
Sorted by citations
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
Strategies to Inhibit Myc and Their Clinical Applicability
Whitfield, J. R., Beaulieu, M.-È., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 303
Glutamine Metabolism in Cancer
Li, T., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_2 · Cited by 242
O’Connor, C. M., Perl, A. L., Léonard, D., Sangodkar, J., & Narla, G. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.008 · Cited by 185
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Vaseva, A. V., Blake, D. R., Gilbert, T. S. K., Ng, S., Hostetter, G. H., Azam, S. H., Ozkan‐Dagliyan, I., Gautam, P., Bryant, K. L., Pearce, K. H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.001 · Cited by 187
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 150
Self-citationFarrell, A. S., Joly, M. M., Allen-Petersen, B. L., Worth, P. J., Lanciault, C., Sauer, D., Link, J. M., Pelz, C., Heiser, L. M., Morton, J. P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01967-6 · Cited by 131
Self-citationGlutamine Metabolism in Cancer
Li, T., Copeland, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_2 · Cited by 134
Targeting PP2A in cancer: Combination therapies
Mazhar, S., Taylor, S. E., Sangodkar, J., & Narla, G. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.08.020 · Cited by 130
Target c-Myc to treat pancreatic cancer
Ala, M. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.2017223 · Cited by 119
Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Kauko, O., & Westermarck, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.005 · Cited by 111
The long journey to bring a Myc inhibitor to the clinic
Whitfield, J. R., & Soucek, L. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202103090 · Cited by 101
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56
Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., et al. (2017) · The EMBO Reports · doi:10.15252/embr.201642788 · Cited by 95
Self-citationLiu, H., Gu, Y., Wang, H., Yin, J., Zheng, G., Zhang, Z., Lu, M., Wang, C., & He, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3818 · Cited by 96
Pan, X., Pei, J., Wang, A., Wen, S., Feng, L., Bu, F., Zhu, Y., Zhang, L., Wang, G., & Ouyang, L. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.022 · Cited by 95
Lankadasari, M. B., Aparna, J. S., Mohammed, S., James, S., Aoki, K., Binu, V. S. N., Nair, S., & Harikumar, K. B. (2018) · Theranostics · doi:10.7150/thno.25308 · Cited by 88
Allen-Petersen, B. L., Risom, T., Feng, Z., Wang, Z., Jenny, Z. P., Thoma, M. C., Pelz, K. R., Morton, J. P., Sansom, O. J., Lopez, C. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0717 · Cited by 85
Self-citationActivation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer
Chien, W., Sun, Q.-Y., Lee, K. L., Ding, L.-W., Wuensche, P., Torres-Fernandez, L. A., Tan, S. Z., Tokatly, I., Zaiden, N., Poellinger, L., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.01.002 · Cited by 80
Concepts to Target MYC in Pancreatic Cancer
Wirth, M., Mahboobi, S., Krämer, O. H., & Schneider, G. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0050 · Cited by 81
The role of CIP2A in cancer: A review and update
Soofiyani, S. R., Hejazi, M. S., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.146 · Cited by 72
De, P. K., Carlson, J. H., Leyland-Jones, B. R., & Dey, N. (2014) · Oncotarget · doi:10.18632/oncotarget.2127 · Cited by 72
Blake, D. R., Vaseva, A. V., Hodge, R. G., Kline, M. P., Gilbert, T. S. K., Tyagi, V., Huang, D., Whiten, G. C., Larson, J. E., Wang, X., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav7259 · Cited by 71
Self-citationParasido, E., Avetian, G. S., Naeem, A., Graham, G. T., Pishvaian, M. J., Glasgow, E. F., Mudambi, S., Lee, Y., Ihemelandu, C. U., Choudhry, M. U., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0191 · Cited by 68
Raman, D., & Pervaiz, S. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101105 · Cited by 58
Liu, C., Huang, T., Chen, Y., Chen, J.-L., Chu, P., Huang, C.-T., Wang, W.-L., Lau, K.-Y., Dai, M., Shiau, C., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.032 · Cited by 52
Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis
Enjoji, S., Yabe, R., Tsuji, S., Yoshimura, K., Kawasaki, H., Sakurai, M., Sakai, Y., Takenouchi, H., Yoshino, S., Hazama, S., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0393 · Cited by 49
Self-citationDeregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity
Risom, T., Wang, X., Liang, J. B., Zhang, X., Pelz, C., Campbell, L. G., Eng, J., Chin, K., Farrington, C. C., Narla, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126390 · Cited by 48
Self-citationProtein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers
Farrington, C. C., Yuan, E., Mazhar, S., Izadmehr, S., Hurst, L., Allen-Petersen, B. L., Janghorban, M., Chung, E. M., Wolczanski, G., Galsky, M. D., et al. (2020) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)49933-9 · Cited by 47
Self-citationmiR-21-5p promotes lung adenocarcinoma progression partially through targeting SET/TAF-Iα
Zhong, J., Ren, X., Chen, Z., Zhang, H., Zhou, L., Yuan, J., Li, P., Chen, X., Liu, W., Wu, D., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.06.014 · Cited by 41
Glucose Metabolism Reprogrammed by Overexpression of IKKϵ Promotes Pancreatic Tumor Growth
Zubair, H., Azim, S., Srivastava, S. K., Ahmad, A., Bhardwaj, A., Khan, M. A., Patel, G. K., Arora, S., Carter, J. E., Singh, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1666 · Cited by 40
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
Kim, M.-O., Choe, M. H., Yoon, Y. N., Ahn, J., Yoo, M., Jung, K., An, S., Hwang, S., Oh, J. S., & Kim, J. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.009 · Cited by 39
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers
Farrington, C. C., Yuan, E., Mazhar, S., Izadmehr, S., Hurst, L., Allen-Petersen, B. L., Janghorban, M., Chung, E. M., Wolczanski, G., Galsky, M. D., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011443 · Cited by 42
Self-citationA comprehensive and perspective view of oncoprotein SET in cancer
Bayarkhangai, B., Noureldin, S., Yu, L., Zhao, N., Gu, Y., Xu, H., & Guo, C. (2018) · Cancer Medicine · doi:10.1002/cam4.1526 · Cited by 40
Hu, X., Garcia, C., Fazli, L., Gleave, M. E., Vitek, M. P., Jansen, M., Christensen, D. J., & Mulholland, D. J. (2015) · Scientific Reports · doi:10.1038/srep15182 · Cited by 37
Self-citationLiu, H., Gu, Y., Yin, J., Zheng, G., Wang, C., Zhang, Z., Deng, M., Liu, J., Jia, X., & He, Z. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.08.010 · Cited by 36
The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias
Pippa, R., & Odero, M. D. (2020) · Cells · doi:10.3390/cells9030544 · Cited by 38
The interaction of SET and protein phosphatase 2A as target for cancer therapy
Dacol, E. C., Wang, S., Chen, Y., & Lepique, A. P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188578 · Cited by 35
Cristóbal, I., Gónzález-Alonso, P., Daoud, L., Solano, E. C., Torrejón, B., Manso, R., Madoz‐Gúrpide, J., Rojo, F., & García‐Foncillas, J. (2015) · Marine Drugs · doi:10.3390/md13063276 · Cited by 32
Pippa, R., Dominguez, A., Malumbres, R., Endo, A., Arriazu, E., Marcotegui, N., Guruceaga, E., & Odero, M. D. (2016) · Oncotarget · doi:10.18632/oncotarget.9840 · Cited by 32
Shu, G., Zhang, L., Jiang, S., Cheng, Z., Wang, G., Huang, X., & Yang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9603 · Cited by 31
Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review
Cristóbal, I., Madoz‐Gúrpide, J., Manso, R., Gónzález-Alonso, P., Rojo, F., & García‐Foncillas, J. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1162774 · Cited by 29
Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer
Hung, M., & Chen, K. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1336226 · Cited by 29
Almeida, L. O., Neto, M. P. C., Sousa, L. O., Tannous, M. A., Curti, C., & Leopoldino, A. M. (2017) · Oncotarget · doi:10.18632/oncotarget.15818 · Cited by 29
McAnulty, J., & DiFeo, A. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249486 · Cited by 28
SET contributes to the epithelial-mesenchymal transition of pancreatic cancer
Mody, H. R., Hung, S. W., Naidu, K., Lee, H., Gilbert, C. A., Hoang, T. T., Pathak, R. K., Manoharan, R., Muruganandan, S., & Govindarajan, R. (2017) · Oncotarget · doi:10.18632/oncotarget.19067 · Cited by 27
Sun, J., Jin, H., Lin, Y., Hou, B., Wu, Z., Li, L., & Yu, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s87183 · Cited by 26
RetractedPP2A and cancer epigenetics: a therapeutic opportunity waiting to happen
Tinsley, S. L., & Allen-Petersen, B. L. (2022) · NAR Cancer · doi:10.1093/narcan/zcac002 · Cited by 26
Self-citationPeroxynitrite promotes serine-62 phosphorylation-dependent stabilization of the oncoprotein c-Myc
Raman, D., Chong, S. J. F., Iskandar, K. B., Hirpara, J. L., & Pervaiz, S. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101587 · Cited by 25
Neale, D. B., Morris, J. C., Verrills, N. M., & Ammit, A. J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108834 · Cited by 25
Cristóbal, I., Torrejón, B., Rubio, J., Santos, A., Pedregal, M., Caramés, C., Zazo, S., Luque, M., Sanz-Álvarez, M., Madoz‐Gúrpide, J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030346 · Cited by 23
The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma
Enjoji, S., Yabe, R., Fujiwara, N., Tsuji, S., Vitek, M. P., Mizuno, T., Nakagawa, T., Usui, T., Ohama, T., & Sato, K. (2015) · Journal of Veterinary Medical Science · doi:10.1292/jvms.15-0193 · Cited by 23
Self-citationJiang, S., Xu, S., Chen, H., Liu, X., Tang, Z., Cui, Y., & Liu, J. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.11.010 · Cited by 23
Molla, M. R., Shimizu, A., Komeno, M., Rahman, N. I. A., Soh, J. E. C., Nguyen, L. K. C., Khan, M. R., Tesega, W. W., Chen, S., Pang, X., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04042-z · Cited by 22
The role of phosphoprotein phosphatases catalytic subunit genes in pancreatic cancer
Hang, J., Lau, S. Y. F., Yin, R., Zhu, L., Zhou, S., Yuan, X., & Wu, L. (2020) · Bioscience Reports · doi:10.1042/bsr20203282 · Cited by 21
Chang, W.-H., Liu, Y., Hammes, E. A., Bryant, K. L., Cerione, R. A., & Antonyak, M. A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102842 · Cited by 23
Sacco, A., Federico, C., Todoerti, K., Ziccheddu, B., Palermo, V., Giacomini, A., Ravelli, C., Maccarinelli, F., Bianchi, G., Belotti, A., et al. (2021) · Blood · doi:10.1182/blood.2020010572 · Cited by 20
Serine/threonine phosphatases in osteoclastogenesis and bone resorption
Karkache, I. Y., Damodaran, J. R., Molstad, D. H. H., & Bradley, E. W. (2020) · Gene · doi:10.1016/j.gene.2020.145362 · Cited by 20
Stable SET knockdown in breast cell carcinoma inhibits cell migration and invasion
Li, J., Yang, X., Ren, X., Meng, X.-J., Huang, H., Zhao, Q.-H., Yuan, J., Hong, W., Xia, B., Huang, X., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.013 · Cited by 19
Tian, L., Zhang, X., Haesen, D., Bravo, J., Fominaya, J. M., Choquet, S., Zini, J. M., Loisel, S., Waelkens, E., Janssens, V., et al. (2017) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-017-9633-1 · Cited by 20
Phosphatases and solid tumors: focus on glioblastoma initiation, progression and recurrences
Dedobbeleer, M., Willems, E., Freeman, S. D., Lombard, A., Goffart, N., & Rogister, B. (2017) · Biochemical Journal · doi:10.1042/bcj20170112 · Cited by 19
Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth
Williams, A. P., Garner, E. F., Waters, A. M., Stafman, L. L., Aye, J. M., Markert, H. R., Stewart, J. E., & Beierle, E. A. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.09.011 · Cited by 18
Gao, D., Nyalali, A. M. K., Hou, Y., Xu, Y., Zhou, J., Zhao, W., Huang, B., & Li, F. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01773-8 · Cited by 16
Fujiki, H., Sueoka, E., Watanabe, T., Komori, A., & Suganuma, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04800-4 · Cited by 15
Rationale for MYC imaging and targeting in pancreatic cancer
Schneider, G., Wirth, M., Keller, U. B., & Saur, D. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00843-1 · Cited by 15
Mambro, A. D., & Esposito, M. T. (2022) · Bioscience Reports · doi:10.1042/bsr20221280 · Cited by 12
The next decade of SET: from an oncoprotein to beyond
Yao, H., Zhang, M., & Wang, D. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad082 · Cited by 11
The Pivotal Role of Protein Phosphatase 2A (PP2A) in Brain Tumors
Cucinotta, L., Filippone, A., Casili, G., Lanza, M., Bova, V., Capra, A. P., Giuffrida, R., Colarossi, C., Sciacca, D., Paterniti, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415717 · Cited by 11
Kohyanagi, N., Kitamura, N., Ikeda, S., Shibutani, S., Sato, K., & Ohama, T. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105584 · Cited by 11
GnRH regulates the expression of its receptor accessory protein SET in pituitary gonadotropes
Avet, C., Denoyelle, C., L’Hôte, D., Petit, F., Guigon, C. J., Cohen-Tannoudji, J., & Simon, V. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201494 · Cited by 11
Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma
Goto, R. N., Sobral, L. M., Padovani, K. S., Garcia, C. B., da Silva, G. F., Vitek, M. P., & Leopoldino, A. M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173268 · Cited by 11
Self-citationAKR1B10 dictates c-Myc stability to suppress colorectal cancer metastasis via PP2A nitration
Wu, X., Huang, S., Gao, J., Huang, S., Chen, L., Zhao, Z., Pu, R., Ma, X., Liu, X., He, W., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv6937 · Cited by 10
CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma
Chao, T., Maa, H., Wang, C., Pei, D., Liang, Y., Yang, Y., Chou, S., & Chen, Y. (2016) · Apmis · doi:10.1111/apm.12602 · Cited by 10
Aguilar‐Valdés, A., Noriega, L. G., Tovar, A. R., Ibarra-Sánchez, M. D. J., Sosa‐Hernández, V. A., Maravillas‐Montero, J. L., & Martínez‐Aguilar, J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.03.018 · Cited by 10
Galiger, C., Dahlhaus, M., Vitek, M. P., Debatin, K., & Beltinger, C. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.744984 · Cited by 11
Self-citationMYC and non-small cell lung cancer: A comprehensive review
Kenzerki, M. E., Ahmadi, M., Mousavi, P., & Ghafouri‐Fard, S. (2023) · Human Gene · doi:10.1016/j.humgen.2023.201185 · Cited by 10
Tinsley, S. L., Chianis, E. R. D., Shelley, R. A., Mall, G. K., Dhiman, A., Baral, G., Kothandaraman, H., Thoma, M. C., English, I. A., Daniel, C. J., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03196-w · Cited by 9
Self-citationSET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
Mambro, A. D., Arroyo-Berdugo, Y., Fioretti, T., Randles, M. J., Cozzuto, L., Rajeeve, V., Cevenini, A., Austin, M. J., Esposito, G., Ponomarenko, J. V., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02840-1 · Cited by 9
Lacroix, A., Farhat, R., Robert, A., Brenner, C., Wiels, J., & Germini, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1444973 · Cited by 9
HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity
Dobersch, S., Yamamoto, N., Schutter, A., Cavender, S. M., Robertson, T. M., Kartha, N., Samraj, A. N., Doron, B., Poole, L. A., Wladyka, C. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60129-1 · Cited by 8
Thapa, C. J., Roivas, P., Haataja, T., Permi, P., & Pentikäinen, U. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.650881 · Cited by 8
Kong, J., Li, D., Zhang, S., Zhang, H., Fu, Y., Qian, B., Bei, C., Tan, S., & Zhu, X. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29629 · Cited by 8
RetractedLum, M. A., Jonas, K. A., Parmar, S., Black, A. R., O’Connor, C. M., Dobersch, S., Yamamoto, N., Robertson, T. M., Schutter, A., Giambi, M., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci176093 · Cited by 7
Characterization of SET/I2PP2A Isoforms in Dogs
Yabe, R., Fujiwara, N., Mizuno, T., Usui, T., Ohama, T., & Sato, K. (2014) · Journal of Veterinary Medical Science · doi:10.1292/jvms.14-0209 · Cited by 7
MiR-145-5p regulates granulosa cell proliferation by targeting the SET gene in KGN cells
LINGLING, G., QINGXING, Y., Xu, J., Wang, W., & Lu, D. A. N. (2024) · Journal of Reproduction and Development · doi:10.1262/jrd.2024-053 · Cited by 6
Henry, M. A., Coleman, O., Prashant, P., CLYNES, M. M., & Meleady, P. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6972-2_13 · Cited by 6
Data mining analysis of the PP2A cell cycle axis in mesothelioma patients
Pippa, R., Boffo, S., Odero, M. D., & Giordano, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29414 · Cited by 6
Tozuka, K., Wongsirisin, P., Nagai, S. E., Kobayashi, Y., Kanno, M., Kubo, K., Takai, K., Inoue, K., Matsumoto, H., Shimizu, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93620-y · Cited by 6
Template activating factor-I epigenetically regulates the TERT transcription in human cancer cells
Kato, K., Kawaguchi, A., & Nagata, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-97009-9 · Cited by 5
Upregulated SET Promotes Cell Survival Through Activating Akt/NF-κB Signal in Colorectal Carcinoma
Zhu, J., Shi, L., Du, G., Li, L., & Liu, M. (2020) · Cancer Management and Research · doi:10.2147/cmar.s255930 · Cited by 4
Phosphorylation of protein phosphatase 2A facilitated an early stage of chemical carcinogenesis
Ishii, Y., Kuroda, K., Matsushita, K., Yokoo, Y., Takasu, S., Kijima, A., Nohmi, T., Ogawa, K., & Umemura, T. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.10.009 · Cited by 3
LI, Y., Yu, D., Sheng, W., SONG, H., Li, Y., & Dong, M. (2016) · Oncology Reports · doi:10.3892/or.2016.4592 · Cited by 3
Shah, V. M., & Sears, R. C. (2025) · Current Opinion in Physiology · doi:10.1016/j.cophys.2025.100849 · Cited by 2
Self-citationDistribution of SET/I2PP2A protein in gastrointestinal tissues
Umata, K., Sakai, Y., Ikeda, S., Tsuji, S., Kawasaki, H., Ohama, T., & Sato, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222845 · Cited by 2
Luo, Y., Biswas, H., Makinwa, Y., Liu, S., Dong, Z., Liu, J., Zhang, J., & Zou, Y. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217790 · Cited by 1
Decreased PP2A expression and activity represent a therapeutic target for plexiform neurofibroma
Yue, M., Wang, Y., Gu, J., Zhang, C., Chen, Y., Gao, A., Choi, K., Wu, Z., Wang, Z., Pundavela, J., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02315-w · Cited by 1
Self-citationActivation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC
Pfeffer, C. M., Clifford, S. J., Karim, S. A., Chianis, E. R. D., N, H. B., Gartenhaus, L. E., Kay, E. F., Baral, G., Hoffman, E. G., Utturkar, S. M., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0970 · Cited by 1
Self-citationTargeting PP2A inhibitors as a novel anti-cancer strategy
Ohama, T. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.145.293 · Cited by 1
Matsumoto, C. S. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2016.tde-06072016-105354
Goto, R. N. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2017.tde-23112017-161303
Metadata
- Authors
- Farrell, A. S., Allen-Petersen, B., Daniel, C. J., Wang, X., Wang, Z., Rodriguez, S., Impey, S., Oddo, J., Vitek, M. P., Lopez, C., Christensen, D. J., Sheppard, B., & Sears, R. C.
- Affiliations
- Authors' Affiliations: Departments of 1Molecular and Medical Genetics,
- Oregon Health & Science University (US)
- Oncotide Pharmaceuticals (United States) (US)
- Duke Medical Center (US)
- 2Hematology and Oncology, and
- 3Surgery,
- Corresponding author
- Sears, Rosalie C.
- ORCID
- Venue
- Molecular Cancer Research
- Published
- 2014-06-01
- Volume
- 12
- Issue
- 6
- Pages
- 924-939
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- PMC
- PMC4116560
- OpenAlex
- W2108146440
- Cited by
- 114
- References
- 60
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 4 · 2023: 8 · 2022: 8 · 2021: 12 · 2020: 9 · 2019: 11 · 2018: 10 · 2017: 16 · 2016: 11 · 2015: 6 · 2014: 5
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA129040, R01CA129040, R01CA196228, R41CA165570, R01CA100855, P30CA069533)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- pancreatic cancer, protein phosphatase 2A, CIP2A, c-Myc, PP2A inhibitors, tumor suppressor regulation, c-Myc degradation, tumorigenicity, cell proliferation, cell survival signaling
- MeSH terms
- Animals, Cell Movement, DNA-Binding Proteins, Humans, Pancreatic Neoplasms, Peptides, Transcription Factors, Transfection, Signal Transduction, Gene Expression Regulation, Neoplastic, Mice, SCID, Mice, Inbred NOD, Cell Line, Tumor, Cell Proliferation, Mice, Protein Phosphatase 2, Gene Knockdown Techniques, Histone Chaperones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
